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Background: Non-small cell lung carcinoma (NSCLC) represents approximately 80% of lung cancer cases, and over
60% of these tumors express the epidermal growth factor receptor (EGFR). Activating mutations in the tyrosine
kinase (TK) domain of the EGFR are detected in 10% to 30% of NSCLC patients, and evidence of their presence is a
prerequisite for initiation of first-line therapy with selective TK inhibitors (TKIs), such as gefitinib and erlotinib. To
date, the selection of candidate patients for first-line treatment with EGFR TKIs requires an invasive tumor biopsy
to affirm the mutational status of the receptor. This study was designed to evaluate whether positron emission
tomography (PET) of NSCLC tumor-bearing mice using [11C]erlotinib could distinguish erlotinib-sensitive from
erlotinib-insensitive or erlotinib-resistant tumors.
Methods: Four human NSCLC cell lines were employed, expressing either of the following forms of the EGFR:
(i) the wild-type receptor (QG56 cells), (ii) a mutant with an exon 19 in-frame deletion (HCC827 cells), (iii) a mutant
with the exon 21 L858R point mutation (NCI-H3255 cells), and (iv) a double mutant harboring the L858R and
T790M mutations (NCI-H1975 cells). Sensitivity of each cell line to the anti-proliferative effect of erlotinib was
determined in vitro. In vivo PET imaging studies following i.v. injection of [11C]erlotinib were carried out in nude
mice bearing subcutaneous (s.c.) xenografts of the four cell lines.
Results: Cells harboring activating mutations in the EGFR TK domain (HCC827 and NCI-H3255) were approximately
1,000- and 100-fold more sensitive to erlotinib treatment in vitro, respectively, compared to the other two cell lines.
[11C]Erlotinib PET scans could differentiate erlotinib-sensitive tumors from insensitive (QG56) or resistant (NCI-H1975)
tumors already at 12 min after injection. Nonetheless, the uptake in HCC827 tumors was significantly higher than
that in NCI-H3255, possibly reflecting differences in ATP and erlotinib affinities between the EGFR mutants.
Conclusions: [11C]Erlotinib imaging in mice differentiates erlotinib-sensitive NSCLC tumors from erlotinib-insensitive
or erlotinib-resistant ones.
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The mortality from lung cancer is high and accounts for
almost 30% of cancer-related deaths. Though the overall
death rate from lung cancer is declining, the prognosis of
stage IV non-small cell lung carcinoma (NSCLC) patients
is poor, with a 5-year survival rate lower than 5% [1,2].
NSCLC represents approximately 80% of lung cancer
cases, and over 60% of these tumors express the epidermal
growth factor receptor (EGFR), rendering it a primary* Correspondence: abourbehg@hadassah.org.il
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proaches [1,3-5].
Alterations in the tyrosine kinase (TK) domain of the
EGFR, such as the L858R point mutation and the E746-
A750 deletion mutation, occur in 10% to 15% of Caucasian
and 30% to 50% of Asian NSCLC patients [6]. These
mutations are associated with a distinct pattern of EGFR
downstream signaling and confer ‘oncogene addiction’,
i.e., dependence of cells upon EGFR activity. Thus, in
the presence of these sensitizing mutations, inhibition
of EGFR signaling is detrimental to the cells [7-9].
Low molecular weight TK inhibitors (TKIs) of the
EGFR, such as gefitinib and erlotinib, have been provenis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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patients, whose tumors harbor activating mutations in
the EGFR TK domain. Specifically, in the presence of
such mutations, treatment with a selective EGFR TKI is
associated with superior progression-free survival (PFS),
increased overall response rate (ORR), a more favorable
toxicity profile, and an improved quality of life with
respect to cytotoxic chemotherapy [1,6,10,11]. More-
over, first-line treatment of mutation-negative NSCLC
patients using selective EGFR TKIs is harmful and
worsens PFS. Accordingly, EGFR TKIs are recommended
as first-line treatment only for patients whose tumors har-
bor activating EGFR TK mutations [1,10].
Despite the significant improvement in PFS and ORR,
all patients treated with EGFR TKIs inevitably develop
resistance. Emergence of a secondary mutation in the
TK domain of the receptor, such as the T790M point
mutation, is the most common mechanism of resistance
to EGFR TKIs, accounting for approximately 50% of pa-
tients, whose disease had progressed following treatment
with TKIs [1,6,12,13].
At present, identification of candidate NSCLC patients
for first-line treatment with TKIs requires screening for
the existence of mutations, using tumor genotyping tech-
niques and/or immunohistochemistry (IHC) [1,14]. These
approaches require invasive procedures for tissue biopsies,
which are not always readily accessible for sampling, could
be of insufficient quality, and require time for mutation
analysis. Furthermore, owing to the heterogeneity of tu-
mors vis-à-vis the mutational status of EGFR, the data ob-
tained from tissue samples does not necessarily reflect that
of the entire primary tumor and is of limited value in pre-
dicting the molecular characteristics of distant metastases.
These hurdles have urged the pursuit of alternative,
non-invasive approaches for evaluating and quantifying
the mutational status of EGFR [15,16]. The use of a non-
invasive imaging technique, such as positron emission
tomography (PET), for identifying the mutational status of
the EGFR TK in tumors should facilitate patient stratifica-
tion prior to initiation of treatment with TKIs. Moreover,
since approximately 50% of NSCLC patients treated with
TKIs ultimately develop secondary mutations in the EGFR
TK domain in tumors and consequently resistance to erlo-
tinib treatment, PET should also afford longitudinal moni-
toring of EGFR mutational status in tumors.
During the past decade, numerous radiolabeled EGFR-
targeted agents, namely antibodies and TKIs, have been
investigated as probes for visualizing and quantifying
EGFR expression in tumors using nuclear imaging modal-
ities, such as single photon emission computed tomog-
raphy (SPECT) and PET [16-29]. Notably, both erlotinib
and gefitinib have been labeled with positron-emitting iso-
topes and evaluated in preclinical animal models. Reports
on 11C- and 18F-labeled gefitinib imaging in tumor-bearingmice indicated that [11C]gefitinib has more potential than
its fluorine-18-labeled congener, although to date, neither
has progressed into clinical trials [26,29]. Conversely, re-
ports on [11C]erlotinib have revealed its added value in
imaging EGFR mutant-positive tumors not only in mice
[19,24], but also in humans [18,20,28]. Hitherto, elevated
tumor uptake of [11C]erlotinib has been demonstrated only
in tumors harboring EGFR exon 19 deletions compared to
tumors without activating EGFR mutations [18,19,24,28].
However, the extent to which [11C]erlotinib PET could
identify NSCLC tumors that harbor other commonly
detected TK mutations, such as the activating exon 21
L858R point mutation and the T790M gate-keeper mu-
tation, which confers resistance to TKI therapy, has not
been reported.
In the current study, we sought to further explore the
potential of [11C]erlotinib in differentiating erlotinib-
sensitive tumors from erlotinib-insensitive or erlotinib-
resistant ones. To this end, four different human NSCLC
cell lines were employed, two of which express the com-
monly encountered mutations in the EGFR TK domain
(delE746-A750 mutation and L858R point mutation)
and two additional lines expressing the secondary T790M
mutation or wild-type EGFR (wtEGFR). [11C]Erlotinib
PET/CT scans were carried out in athymic nude mice
grafted with subcutaneous (s.c.) xenografts of these tumor
cell lines. The presented results indicate that [11C]erlotinib
scans could distinguish NSCLC tumors that express ac-
tivating mutations in the EGFR TK domain and are sen-
sitive to erlotinib treatment, from tumors that harbor
wtEGFR or the double-mutated (L858R + T790M) re-
ceptor and do not respond to erlotinib therapy. This
data further substantiate the potential of [11C]erlotinib
PET as a non-invasive tool to identify NSCLC patients
who are most likely to benefit from treatment with TKIs
and to monitor the mutational status of EGFR during
the course of treatment.
Methods
General
Insulin, transferrin, HEPES, and sodium pyruvate were
purchased from Biological Industries (BI) (Kibbutz Beit
Haemek, Israel). Sodium selenite, hydrocortisone, etha-
nolamine, O-phosphorylethanolamine, 3,3′,5-triiodo-L-
thyronine (T3), and bovine serum albumin (BSA) were
purchased from Sigma-Aldrich (Rehovot, Israel). Recom-
binant human EGF was purchased from PeproTech Asia
(Rehovot, Israel).
Hsd:Athymic Nude-Fox1nu mice (male, 4 to 5 weeks)
were obtained from Harlan (Rehovot, Israel). All animal
studies were conducted under a protocol approved by
the Animal Research Ethics Committee of the Hebrew
University of Jerusalem and in accordance with its guide-
lines. Animals were allowed to acclimate for at least 3
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routinely kept in 12-h light/dark cycles and provided with
food and water ad libitum.
Cell culture
The following human NSCLC cell lines were employed:
QG56, HCC827, NCI-H1975, and NCI-H3255. The latter
were purchased from the National Cancer Institute - Div-
ision of Cancer Treatment and Diagnosis (NCI-DCTD)
tumor repository (Frederick, MD, USA) and were regularly
maintained in ACL-4 medium, containing insulin (0.02
mg/mL), transferrin (0.01 mg/mL), sodium selenite (25
nM), hydrocortisone (50 nM), EGF (1 ng/mL), ethanol-
amine (0.01 mM), O-phosphorylethanolamine (0.01 mM),
triiodothyronine (100 pM), BSA (0.2% (w/v)), HEPES (10
mM), sodium pyruvate (0.5 mM), and L-glutamine (2 mM)
in RMPI-1640 medium (Invitrogen™, Life Technologies,
Carlsbad, MA, USA). HCC827 and NCI-H1975 cells were
maintained in RMPI-1640 (#30-2001, ATCC), and QG56
were grown in RPMI-1640 (Invitrogen™) at 37°C in a hu-
midified atmosphere of 95% air and 5% CO2. All media
were supplemented with fetal bovine serum (FBS, 10%)
and antibiotics (penicillin 104 units/L, streptomycin 10
mg/L) (BI, Israel).
Inhibition of cell growth
QG56 (4,000 cells), HCC827, NCI-H3255 (5,000 cells),
and NCI-H1975 (7,000 cells) were cultured in 96-well
plates. After 24 to 48 h, cells were treated with increas-
ing concentrations (0 to 100 μM) of erlotinib (Cayman
Chemical Company, Ann Arbor, MI, USA). The media
containing erlotinib (0.05% DMSO, 0.1% ethanol) were
freshly prepared and replaced every 24 h. Following 72 h of
treatment, cell growth was determined by methylene blue
assay [30]. The median inhibitory concentration (IC50) of
erlotinib for cell growth of each cell line was calculated
using GraphPad Prism 5.0 software. Experiments were re-
peated thrice for each cell line, in three to six replicates per
tested concentration.
NSCLC xenografts
Mice were anesthetized with isoflurane (1% to 2% in oxy-
gen) and injected s.c. in each front flank with a suspension
of five million cells in a medium containing Matrigel (BD
Biosciences, Beit Haemek, Israel, 20% (v/v)).
Western blot
Cell lysates and tumor tissue extracts were prepared in
cold (0°C to 4°C) modified RIPA buffer [31], supple-
mented with protease inhibitor cocktail for mammalian
tissues (P8340, Sigma, 1%). Equal amounts of each sam-
ple (30 μg of total protein) were loaded and separated by
SDS-PAGE (10%). Proteins were electrophoretically trans-
ferred to a nitrocellulose membrane, and the latter wasblocked in 3% BSA in TBST buffer (50 mM Tris-HCl, pH
7.5, 0.1% Tween 20, and 150 mM NaCl) for 30 min.
Corresponding parts of the membrane were incubated
overnight (4°C with gentle shake) with either of the fol-
lowing primary antibodies, diluted in 3% BSA/TBST: (1)
rabbit polyclonal EGFR 1005 antibody (sc-03, Santa
Cruz Biotechnology Inc., Dallas, TX, USA), (2) mouse
monoclonal phosphotyrosine PY20 antibody (sc-508, Santa
Cruz Biotechnology Inc.), or (3) mouse monoclonal anti-β-
actin antibody (mAbcam 8224, Abcam, Cambridge, UK).
The membrane parts were washed thoroughly with TBST
buffer and incubated for 1 h with the corresponding horse-
radish peroxidase-conjugated IgGs (Santa Cruz Biotechnol-
ogy Inc.) in 3% BSA/TBST. Finally, the membranes were
washed in TBST, and immunoreactive proteins were visu-
alized using the EZ-ECL kit (BI, Israel). Densitometry was
performed using TINA 2.10 g software, and the intensity
of each EGFR band was normalized to that of the corre-
sponding β-actin band to correct for possible differences in
the content of total loaded protein.
[11C]Erlotinib synthesis
The radiosynthesis of [11C]erlotinib was based on a
previously published procedure [19,20], with slight mod-
ifications. [11C]CO2 (50.5 ± 2 GBq (n = 25)) was trapped
at −160°C. Subsequently, the temperature of the cooling
trap was increased to −5°C, and the activity was trans-
ferred by a stream of argon (40 mL/min) into the first
reactor at −50°C, containing 300 μL of 0.25 N lithium
aluminum hydride (ABX, Radeberg, Germany) in dry
tetrahydrofuran. After 2.5 min, the solvent was removed
under reduced pressure, and the reactor temperature
was increased to 160°C. Next, hydroiodic acid (0.5 mL,
Merck, White House Station, NJ, USA) was added, and
[11C]CH3I was distilled through a NaOH column (Merck)
under argon flow (25 mL/min) and transferred into a sec-
ond reactor at −15°C, containing 10 mg of 6-O-desmethyl
erlotinib (OSI-774, Selleck Chemicals, Houston, TX, USA)
dissolved in 0.3 mL N,N-dimethylformamide, containing
3.5 mg of sodium hydride. At the end of the 1-min distilla-
tion step, 20.6 ± 1 GBq (n = 25) was trapped in the second
reactor. The reactor was sealed and heated to 90°C for
1.5 min. Then, the reactor temperature was increased to
120°C for an additional 5 min. Following a 6.5-min reac-
tion, volatiles were removed under argon flow (at re-
duced pressure) at a temperature of 90°C. The mixture
was cooled to 40°C, 0.6 mL of acetonitrile/water was
added, and the crude product was injected into a semi-
preparative HPLC column, equipped with a variable wave-
length UV detector (254 nm) and a radioactivity detector
with NaI crystals. A Phenomenex C18 column (5 μm, 10
mm× 250 mm; Torrance, CA, USA) was used, with a mo-
bile phase system of acetonitrile:acetate buffer 0.1 M, pH
3.8 (4:6), at a constant flow rate of 4 mL/min. The retention
Table 1 Sensitivity of four human NSCLC cell lines to the
anti-proliferative effect of erlotinib in vitro




QG56 None (wtEGFR) 8.9 ± 0.5*** No
HCC827 Activating (delE746-A750) 0.004 ± 0.0009 Yes
NCI-H3255 Activating (L858R point
mutation)
0.041 ± 0.007 Yes
NCI-H1975 Double mutation (L858R +
T790M point mutations)
4.3 ± 0.8*** No
***p < 0.001 with respect to HCC827 cells.
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collected into a flask containing 24 mL HPLC water and
350 μL of 1 M NaOH. Subsequently, the solution was
passed through a Sep-Pak Plus C18 cartridge (Waters
Corporation, Milford, MA, USA), which was pre-activated
with 5 mL EtOH, and washed with 10 mL HPLC water
prior to the synthesis. The cartridge was washed with 4 mL
of water, and [11C]erlotinib was eluted using 1.3 mL of
EtOH followed by 11 mL of sterile isotonic saline (B. Braun,
Melsungen, Germany). Quality control analysis was per-
formed on an analytical HPLC, equipped with a variable
wavelength UV detector (254 nm) and a radioactivity
detector with NaI crystals. A Phenomenex C18 column
(5 μm, 4.6 mm × 250 mm) was used, with a mobile
phase system of acetonitrile:acetate buffer 0.1 M, pH 3.8
(37:63) for 30 min, at a constant flow rate of 1 mL/min.
MicroPET/CT studies
Tumor-bearing mice (30 ± 1 g (n = 27)) were anesthetized
with isoflurane (1% to 2.5% in O2) and maintained normo-
thermic using a heating pad. Following a CT attenuation-
correction scan, PET acquisitions were carried out in list
mode using an Inveon™ MM PET-CT small-animal dedi-
cated scanner (Siemens Medical Solutions, Malvern, PA,
USA). PET scans were started at the time of [11C]erlotinib
injection via the lateral tail vein (16.36 ± 0.6 MBq (n = 27))
and lasted for 1 h. Subsequently, mice were maintained at
the same position and injected i.v. with [18F]FDG (5.67 ±
0.2 MBq (n = 24)). After a 40-min uptake period, a second
20-min PET acquisition was performed. Carrier-added
studies were carried out in HCC827 tumor-bearing mice
(n = 5), wherein erlotinib (6.7 mg/kg, dissolved in Cremo-
phor EL/ethanol/saline (1:1:8)) was co-injected with the
radiolabeled compound.
Emission sinograms were normalized and corrected
for attenuation, scatter, randoms, dead time, and decay.
Image reconstruction was performed using Fourier rebin-
ning and two-dimensional ordered-subsets expectation
maximization (2D-OSEM), with a voxel size of 0.776 ×
0.776 × 0.796 mm3. Image analysis and quantification were
performed using Inveon Research Workplace 4.2 (Siemens
Medical Solutions). Delineation of tumors' volumes of
interest (VOIs) was performed by manual segmentation,
based on the fused [18F]FDG and CT images, and the cor-
responding [11C]erlotinib time-activity curves (TACs)
were calculated. Distribution of activity was calculated as
the percentage of injected dose per milliliter of tissue
(%ID/mL). Standardized uptake values (SUVs) were calcu-
lated as the product of %ID/mL and the total body weight
of the animal.
Statistics
Statistical analysis was made using GraphPad Prism 5
software. Unless otherwise stated, data is expressed asmean ± SEM. Comparisons of [11C]erlotinib uptake in
tumors in imaging studies were made using one-way
ANOVA, followed by the Bonferroni post hoc test. The
level of significance was regularly set at p < 0.05.
Results
Inhibition of cell growth
Four human NSCLC cell lines expressing different forms
of the EGFR were investigated. Sensitivity of each cell
line to the anti-proliferative effect of erlotinib was evalu-
ated by methylene blue assay and is presented in Table 1.
Two cell lines, HCC827 and NCI-H3255, which express
activating mutations in the EGFR, were erlotinib-sensitive,
having mean IC50 values of 4 and 41 nM, respectively. Two
additional cell lines, QG56 (expressing wtEGFR) and NCI-
H1975 (expressing the L858R +T790M point mutations),
were significantly less sensitive to erlotinib treatment, with
mean IC50 values of 8.9 and 4.3 μM, respectively. Thus,
in vitro, NCI-H3255 and HCC827 cells were 100- to 1,000-
fold more sensitive to the anti-proliferative effect of erloti-
nib compared to QG56 and NCI-H1975 cells. In agreement
with previous reports, Western blot analysis (Figure 1) in-
dicated that the sensitivity to erlotinib treatment could
not be attributed to differences in total EGFR or EGFR-
associated phosphotyrosine (PY) levels, since neither of
those correlated with erlotinib sensitivity of the tested cell
lines [14,32,33].
[11C]Erlotinib synthesis
[11C]Erlotinib was obtained after an approximately 40-min
synthesis, including formulation, with an average radio-
activity of 2.42 ± 0.3 GBq (n = 25) in 12.3 mL of 10% EtOH/
saline. The average specific activity at the end of synthesis
was 26.14 ± 2.5 GBq/μmol (n = 25), and the radiochemical
purity was above 97%.
MicroPET/CT studies
PET acquisitions of tumor-bearing mice were carried out
for 1 h following i.v. injection of [11C]erlotinib. Subse-
quently, mice were injected with [18F]FDG and scanned
again 40 min after injection. The [18F]FDG scans served a
Figure 1 Representative Western blots of four human NSCLC
cell lysates comparing the extent of EGFR and phospho-EGFR
expression. β-actin served as a reference for equal loading.
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the tumor's VOI, particularly in cases where [11C]erlotinib
uptake in tumor was not prominent (Figure 2).
TACs representing the kinetics in tumors following
[11C]erlotinib injection are presented in Figure 3, reveal-
ing distinct differences between erlotinib-sensitive and
erlotinib-insensitive tumors. The uptake in both sensi-
tive tumors, HCC827 and NCI-H3255, was significantly
higher than that observed in QG56 and NCI-H1975 tu-
mors, already at 12 min after injection and throughout
the 60-min scan (Figure 3, Table 2). Thus, [11C]erlotinib
could clearly distinguish erlotinib-sensitive tumors from
insensitive ones. Nonetheless, whereas the uptake in
HCC827 tumors was high and sustained (SUV > 0.6
starting 12 min after injection), the peak SUV in NCI-
H3255 tumors was 0.43, at the same time point, further
declining to 0.33 at 1 h (Figure 3). In addition, the up-
take in HCC827 tumors was specific, as revealed in
blocking studies, wherein more than 50% reduction in
tumor uptake was measured after administration of
non-labeled erlotinib in excess. Notably, the kinetics of
[11C]erlotinib in HCC827 tumors in blocking studies
was comparable to that measured in NCI-H3255 tumors
without the addition of carrier in excess.
Western blot
The relative expression of total EGFR and EGFR-associated
PY levels in the four investigated NSCLC tumors was eval-
uated by Western blot analysis. The results illustrated
in Figure 4 indicated HCC827 as those expressing the
highest levels of EGFR, followed by NCI-H3255 tumors(approximately 73%), NCI-H1975 (approximately 65%),
and QG56 tumors (approximately 43%). Moreover, the
latter also had significantly lower EGFR-associated PY
levels, compared to the other three tumors, wherein
similar levels of EGFR-PY were detected.
Discussion
Target-specific TKIs, peptides, and antibodies have paved
the way to a more personalized treatment of cancer,
wherein therapy is tailored based on the molecular charac-
teristics of the patients' tumors rather than on tumor sta-
ging and histopathology alone [27,34-36]. Nuclear
medicine imaging techniques, such as PET and SPECT,
offer a highly sensitive and non-invasive means for de-
tecting and quantifying the expression of molecular tar-
gets in vivo. Thus, upon development of a suitable
radiolabeled pharmaceutical, one could potentially
visualize and quantify the expression of specific target
proteins in the entire body in a non-invasive, longitu-
dinal manner, instead of relying on site-specific, invasive
tissue sampling. This approach could not only simplify
patient stratification and selection prior to initiation of
targeted therapy, but could also facilitate treatment
monitoring and enable prolonged measurement of
changes in target expression [37].
Specific EGFR TKIs, such as gefitinib and erlotinib,
gained FDA approval for the treatment of advanced
NSCLC in 2003 and 2004, respectively. The clinical data
gathered thus far indicates that only patients whose tu-
mors harbor distinct activating mutations in the TK do-
main of the receptor are likely to benefit from first-line
treatment with EGFR TKIs. These mutations, typically
exon 19 in-frame deletions (approximately 45%) and the
L858R point mutation in exon 21 (40% to 45%), are de-
tected in 10% to 30% of NSCLC patients [38,39]. The
relatively limited prevalence of these sensitizing mutations
requires that the EGFR mutational status be verified prior
to the initiation of first-line therapy with EGFR TKIs. To
date, targeted mutation testing uses specific and sensitive
methods, yet it requires tumor biopsy. This approach is in-
vasive and lengthy with regard to the time required for
mutation analysis and provides information about the sam-
pled site alone. Moreover, it is not favorable for obtaining
molecular information in the long term, as would be
required during EGFR TKI therapy, owing to the devel-
opment of secondary mutations in the receptor and sub-
sequent resistance to TKI treatment [1,6].
The present work further highlights the potential of
[11C]erlotinib PET in discriminating erlotinib-sensitive
NSCLC tumors from erlotinib-insensitive or resistant
tumors. This methodology should provide sufficient in-
formation vis-à-vis the potential clinical benefit of pa-
tients from EGFR TKI therapy, hopefully circumventing
the need for invasive tissue biopsies.
Figure 3 TACs representing NSCLC tumor kinetics following
injection of [11C]erlotinib. Tumor TACs were obtained after
i.v. injection of [11C]erlotinib into NSCLC tumor-bearing mice,
demonstrating increased radioactivity uptake in erlotinib-sensitive
tumors (HCC827 and NCI-H3255) compared to insensitive (QG56)
or resistant (NCI-H1975) ones. The number of scanned tumors is
indicated in brackets. **p < 0.01 and ***p < 0.001.
Figure 2 Representative PET/CT slice images of NSCLC tumor-bearing mice. The images were taken following sequential injections of
[11C]erlotinib (a-d) and [18F]FDG (e-h) into each mouse, demonstrating (arrowheads) [11C]erlotinib uptake in erlotinib-sensitive tumors (b, c) and in
erlotinib-insensitive ones (a, d). [11C]Erlotinib and [18F]FDG images depict the summation of radioactivity uptake from 30 to 60 min and 40 to 60 min
after injection, respectively. Each set of [11C]erlotinib and [18F]FDG images was normalized to the same scale.
Abourbeh et al. EJNMMI Research  (2015) 5:4 Page 6 of 10Four human NSCLC tumors were employed in this
study, expressing wtEGFR (QG56), the commonly encoun-
tered activating mutations in the TK domain of the recep-
tor, namely the delE746-A750 mutation (HCC827) and the
L858R point mutation (NCI-H3255) or the L858R +
T790M mutations (NCI-H1975). The latter cell line was
selected since secondary mutations in the TK domain, such
as the T790M mutation, are encountered in approximately
50% of EGFR TKI-treated patients, who develop resistance
to therapy [1,6,38]. The effect of erlotinib on cell prolifera-
tion was evaluated in vitro for each cell line, and theTable 2 Tumor SUVs at early (12 min) and late (60 min)
time points after [11C]erlotinib injection
Tumor type Early SUV Late SUV
QG56 0.338 ± 0.039* (6) 0.195 ± 0.010**, *** (6)
HCC827 0.598 ± 0.013 (4) 0.709 ± 0.069 (7)
HCC827 + block 0.424 ± 0.046** (5) 0.298 ± 0.029** (5)
NCI-H3255 0.427 ± 0.014** (6) 0.328 ± 0.089** (6)
NCI-H1975 0.326 ± 0.032* (8) 0.209 ± 0.028**, *** (8)
Results are presented as mean ± SD, and the number of scanned tumors is
indicated in brackets. *p < 0.001 with respect to HCC827 and NCI-H3255
tumors. **p < 0.001 with respect to HCC827 tumors. ***p < 0.01 with respect to
NCI-H3255 tumors.
Figure 4 Representative Western blots of NSCLC tumor extracts, demonstrating total EGFR and phospho-EGFR levels in tumors. n = 3
per group. β-actin served as a reference for equal loading.
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Table 1. The results indicate that HCC827 and NCI-H3255
cells were significantly more sensitive to erlotinib treat-
ment compared to QG56 and NCI-H1975 cells, having
mean IC50 values of 4 and 40 nM, compared to 8.9 and
4.3 μM, respectively.
Subsequently, [11C]erlotinib PET acquisitions of tumor-
bearing mice were carried out in order to determine
whether the differences between cell lines vis-à-vis erloti-
nib sensitivity in vitro could be translated into distinct
patterns of [11C]erlotinib tumor uptake in vivo. Since
[11C]erlotinib uptake in tumors was not always evident
(Figure 2), an [18F]FDG PET acquisition was carried out
following each [11C]erlotinib scan, as aforementioned. The
TACs of [11C]erlotinib uptake in tumors are illustrated in
Figure 3, revealing statistically significant higher uptake of
[11C]erlotinib in erlotinib-sensitive tumors vs. erlotinib-
insensitive or erlotinib-resistant tumors. This differential
uptake was measured as early as 12 min after [11C]erloti-
nib injection and had lasted throughout the 60-min
scan period. Interestingly, however, whereas the profile
of [11C]erlotinib uptake in both QG56 and NCI-H1975
tumors was almost identical, the uptake of [11C]erlotinib
in HCC827 tumors was notably different from that
observed in NCI-H3255 tumors. Specifically, [11C]erlotinib
uptake in HCC827 tumors was relatively high and persist-
ent, with mean SUVs of 0.60 and 0.71 at 12 and 60 min,
respectively, compared to corresponding mean SUVs of
0.43 and 0.33 for NCI-H3255 tumors (Table 2). Further-
more, the TACs obtained for NCI-H3255 tumors were
highly similar to those of HCC827 after co-administration
of non-labeled erlotinib in excess.
Several factors could account for the observed differ-
ences in both kinetics and absolute [11C]erlotinib uptake
values in HCC827 vs. NCI-H3255 tumors. First, the over-
all concentration of the target protein (Bmax) is expected
to affect the extent of ligand binding [24,40]. Western blot
analysis of tumor lysates indicated approximately 30%
lower levels of EGFR in NCI-H3255 tumors compared to
HCC827 (Figure 4), consistent with the approximately
30% lower SUV of [11C]erlotinib in NCI-H3255 tumors at
12 min after injection, the time of peak radioactivityuptake in these tumors (Figure 3). Still, differences in
EGFR expression in tumors per se are most likely not the
main determinant of the overall observed differences in
[11C]erlotinib tumor uptake. As was recently demon-
strated, elevated expression of EGFR or phospho-EGFR,
such as that observed in U87ΔEGFR glioma tumors, does
not guarantee enhanced uptake of [11C]erlotinib [24].
Similarly, our results indicate that although higher levels
of EGFR and phospho-EGFR were measured in NCI-
H1975 compared to QG56 tumors (Figure 4), the
uptake of [11C]erlotinib in the two xenografts was com-
parable (Figure 3, Table 2). Thus, the cumulative evi-
dence points to the mutational status of the EGFR TK
domain rather than the level of EGFR expression as the
major factor affecting [11C]erlotinib uptake in tumors.
Nonetheless, when comparing the uptake of [11C]erloti-
nib in tumors that harbor activating mutations in the
EGFR TK domain, the expression levels of the receptor
should come into play [24].
Then, different binding affinities of the EGFR TK mu-
tants to both adenosine triphosphate (ATP) and erlotinib
could explain the heterogeneous kinetics of [11C]erlotinib
in the two erlotinib-sensitive tumors. Carey et al. have
demonstrated that compared to wtEGFR, the delE746-
A750 and L858R mutants had significantly lower binding
affinities to ATP, with corresponding approximately 26-
and approximately 2-fold higher Michaelis-Menten con-
stants (KM) with respect to the wtEGFR [41]. At the same
time, these mutants were also reported to hold higher af-
finities to erlotinib, with respective 5.3- and 2.8-fold lower
inhibition constant values (Ki), compared to the wild-type
receptor. Consequently, tumors harboring the delE746-
A750 mutation would be expected to bind [11C]erlotinib
more avidly than those expressing the L858R mutation.
Increased uptake of [11C]erlotinib in tumors harboring
the delE746-A750 mutation compared to wtEGFR has
been demonstrated in both NSCLC patients [18] and
mouse models [19,24]. The present results are in good
agreement with those published by Petrulli et al. [24],
with respect to the sustained uptake of [11C]erlotinib in
HCC827 tumors, albeit lower mean SUVs were measured
in the current study (0.7 vs. approximately 1.3 at 60 min
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sured in this study could partly be attributed to the lower
specific activity of [11C]erlotinib obtained here (26.14 ± 2.5
GBq/μmol), compared to that published by Petrulli and
colleagues (159.1 ± 48 MBq/nmol) [24], resulting in a
higher injected mass of non-labeled carrier. Based on
the results of the present research, a proposed correl-
ation between the injected erlotinib mass and the SUV
of HCC827 tumors at 60 min after injection (SUV60 min)
is presented in Figure 5, suggesting that the relationship
between the two is exponential rather than linear. Thus,
following injection of an 11-fold higher carrier mass
(4.4 vs. 0.4 nmol), the SUV60 min of [
11C]erlotinib in
HCC827 tumors had decreased by approximately 21%
(from 0.8 to 0.63). Consistent with this notion, an excess
non-labeled erlotinib dose of approximately 500 nmol,
such as that administered in this study, should result in
an SUV60 min of approximately 0.3 for HCC827 tumors,
as was indeed obtained in the blocking experiments
(Figure 5). Moreover, if the proposed relation between
the injected carrier mass and the SUV60 min of HCC827
tumors is valid, increasing the blocking dose from 6.7
mg/kg to approximately 30 mg/kg should further reduce
the SUV60 min of HCC827 to approximately 0.2, a value
lower than the measured SUV60 min for NCI-H3255 tu-
mors (0.33) and similar to that obtained in QG56 and
NCI-H1975 tumors (0.2) (Figure 3, Table 2). This possi-
bility is under investigation.
In the current study, calculation of [11C]erlotinib up-
take in tumors relied on SUV measurements rather than
on kinetic parameters, such as the volume of distribu-
tion (VT) or the binding potential (BP). Compared to
SUV, which does not distinguish target-specific from
non-specific binding,VT and BP reflect the specific bind-
ing and are therefore more sensitive measures of Bmax.Figure 5 Inverse correlation between [11C]erlotinib uptake in
HCC827 tumors at 60 min after injection and injected carrier
mass. n = 12. The last point on the right represents the administered
blocking dose (6.7 mg/kg, n = 5).Nonetheless, the ability to distinguish significant differ-
ences in [11C]erlotinib uptake between erlotinib-sensitive
and erlotinib-resistant tumors using SUVs suggests that
a more pronounced difference would have been observed
had a kinetic analysis been performed, and provides an
initial proof-of-concept prior to the validation by full kin-
etic analysis.
In addition to [11C]erlotinib, the use of 3′-deoxy-3′-
[18F]fluorothymidine ([18F]FLT) PET as a non-invasive
tool for identifying TKI-responsive NSCLC tumors has
been reported in preclinical mouse models and in humans
[42-45]. Commonly, these studies measured the change in
[18F]FLT tumor uptake prior to and after initiation of EGFR
TKI therapy, to predict response to treatment. Albeit less
straightforward than [11C]erlotinib scans, this approach
has successfully differentiated TKI-sensitive NSCLC tu-
mors from unresponsive ones. Notably, [18F]FLT PET
scans in NSCLC tumor-bearing mice have demonstrated
their utility in identifying TKI-resistant tumors, which
harbor the most frequently encountered mutations as-
sociated with TKI resistance, i.e., the secondary T790M
mutation [44] and MET amplification [43]. In this study,
the potential of [11C]erlotinib PET in differentiating TKI-
resistant tumors that contain the T790M mutation from
TKI-sensitive tumors has been demonstrated. The utility
of this approach to identify TKI-resistant NSCLC tumors
with MET amplification warrants further investigation.
Conclusions
The present study illustrates the usage of [11C]erlotinib
PET for diagnosing the commonly encountered EGFR
TK mutations in NSCLC patients and for discriminating
erlotinib-sensitive tumors from erlotinib-insensitive or
erlotinib-resistant tumors. To the best of our knowledge,
this is the first demonstration of increased [11C]erlotinib
uptake in NSCLC tumors harboring the L858R point
mutation. Overall, these data further corroborate the po-
tential of [11C]erlotinib PET in identifying patients who
are likely to benefit from EGFR TKI therapy.
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